Clinical trials: Advanced Solid Tumor, completed
Advanced Solid Tumors, Lymphomas
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
The purpose of this study was to determine the safety profile, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to characterize the pharmacokinetic (PK) profile of alisertib twice daily (BID) dosing for 7 days…
- Trial name
- NCT01512758
- Testing
- Alisertib
- Where
- Singapore
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor, KRAS Mutation
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
This study is no longer open to new participants. It was a study in adults with advanced cancer in the stomach and oesophagus. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Trial name
- NCT06056024
- Testing
- BI 3706674
- Where
- 17 sites in United States, Japan and 2 more
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Advanced Incurable Solid Malignancy
Study of GemOx and Vandetanib in Advanced Solid Malignancy
This is a research study that will try to find the highest and safest dose of an experimental drug, vandetanib, that can be given in combination with two standard chemotherapy agents, gemcitabine and oxaliplatin, to subjects with…
- Trial name
- NCT00660725
- Testing
- Vandetanib, Gemcitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Leonard Appleman
Advanced Solid Tumors, Metastatic Solid Tumors
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
This study is an open-label, multicenter, first-in-human, Phase I, dose escalation study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of JSKN003 in subjects with advanced inoperable or metastatic…
- Trial name
- NCT05494918
- Testing
- JSKN003
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Alphamab (Australia) Co Pty Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
A phase I study is conducted to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), safety and pharmacokinetics (PK) profile of a single agent CKD-516 injection on a weekly schedule in patients with advanced…
- Trial name
- NCT01028859
- Testing
- CKD-516 inj
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor
M6620 First in Human Study
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
- Trial name
- NCT02157792
- Testing
- M6620, Gemcitabine, Cisplatin
- Where
- 31 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Solid Tumor, Adult, Chemotherapy Treatment
Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Chemotherapy
The aim of this study is to compare the humeral and thoracic implantation of a central venous access by an implantable device in patients with solids tumors who require intravenous chemotherapy.
- Conditions
- Solid Tumor, Adult, Chemotherapy Treatment, Advanced or Metastasis Stage
- Trial name
- PACPAC-EPOC (NCT03410121)
- Testing
- IPolysite ® Mini série 3108 or Polysite ® Standard, série 4108., Vital Port®Minititanium
- Where
- France
- Volunteers
- 361 people
- Sponsor
- Center Eugene Marquis
Advanced Solid Tumors
Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer
The main objective of this study is to determine the maximum tolerated dose (MTD) of Oral Paclitaxel. Eligible subjects of this study are patients with histologically or cytologically confirmed malignant solid tumor refractory to…
- Trial name
- NCT01491204
- Testing
- Paclitaxel+HM30181
- Volunteers
- 25 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Breast Cancer
Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005991
- Testing
- gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer
A dose escalating phase Ia-b clinical trial of the IGF-1 receptor inhibitor AXL1717 in patients with advanced cancer. The objective is to study the safety and pharmacokinetics of AXL1717 and to define an appropriate Phase 2 dose…
- Trial name
- NCT01062620
- Testing
- AXL1717
- Where
- Sweden
- Volunteers
- 49 people
- Sponsor
- Axelar AB
Solid Tumor, Breast Cancer
A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects
This is an open-label, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Gastrointestinal Cancer
- Trial name
- NCT02742935
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Tumors, Cutaneous T-Cell Lymphoma
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma
- Trial name
- NCT00412997
- Testing
- LBH589
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Novartis
Solid Tumor
Study of AK119 in Subjects With Advanced Solid Tumors
This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.
- Trial name
- NCT05173792
- Testing
- AK119
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Akeso
Gastrointestinal Tumor
Phase I Trial of Combination of FOLFIRI and SOM 230
This is a single-arm, open-label, phase I study of combination therapy with SOM 230 and FOLFIRI. We will utilize a sequential dose-escalation design to define the maximum tolerated dose (MTD) of SOM 230 when combined with…
- Trial name
- NCT01434069
- Testing
- SOM230C LAR, FOLFIRI Infusion
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00486356
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Advanced Solid Tumors
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose…
- Trial name
- NCT02122770
- Testing
- MLN4924, Fluconazole, Itraconazole
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Malignant Solid Tumor, Metastatic EphA2 Positive Cancer
Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
This was a Phase 1, dose-escalation, non-randomized, open-label, single-center study of DS-8895a in patients with advanced or metastatic Ephrin type-A receptor 2 (EphA2)-positive cancers.
- Trial name
- LUD2014-002 (NCT02252211)
- Testing
- DS-8895a 1 mg/kg, DS-8895a 3 mg/kg, DS-8895a 10 mg/kg
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Tumors
A Study of IMC-A12 in Advanced Solid Tumors
In this study, participants will initially receive intravenous (IV) cixutumumab (IMC-A12) every 2 weeks or every 3 weeks for 6 weeks (one cycle).
- Trial name
- NCT01007032
- Testing
- Cixutumumab
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Eli Lilly and Company